Evidence map›Paper›PMID 38336746›Full record

ArticleCancer cell international2024

PHF6 loss reduces leukemia stem cell activity in an acute myeloid leukemia mouse model.

Shengnan Yuan, Mingming Gao, Yizhou Wang, Yanjie Lan, Mengrou Li, Yuwei Du, Yue Li, Wen Ju, Yujin Huang, Ke Yuan and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shengnan Yuan *School of Medical Technology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Mingming Gao *Blood Diseases Institute, Xuzhou Medical University, No. 209, Tongshan Road, Xuzhou, Jiangsu, 221004, China.
Yizhou Wang *Blood Diseases Institute, Xuzhou Medical University, No. 209, Tongshan Road, Xuzhou, Jiangsu, 221004, China.
Yanjie LanDepartment of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100071, China.
Mengrou LiBlood Diseases Institute, Xuzhou Medical University, No. 209, Tongshan Road, Xuzhou, Jiangsu, 221004, China.
Yuwei DuBlood Diseases Institute, Xuzhou Medical University, No. 209, Tongshan Road, Xuzhou, Jiangsu, 221004, China.
Yue LiSchool of Medical Technology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Wen JuBlood Diseases Institute, Xuzhou Medical University, No. 209, Tongshan Road, Xuzhou, Jiangsu, 221004, China.
Yujin HuangBlood Diseases Institute, Xuzhou Medical University, No. 209, Tongshan Road, Xuzhou, Jiangsu, 221004, China.
Ke YuanBlood Diseases Institute, Xuzhou Medical University, No. 209, Tongshan Road, Xuzhou, Jiangsu, 221004, China.
Lingyu ZengSchool of Medical Technology, Xuzhou Medical University, Xuzhou, Jiangsu, China. zengly2000@163.com.
Xuzhou Medical College · CNCapital Medical University · CN

Funding

Jiangsu Provincial Key Research and Development Program BE2022710National Natural Science Foundation of China 82270151the grant of Natural Science Foundation of Jiangsu Province BK20230682the grant of Natural Science Foundation of the Higher Education Institutions of Jiangsu Province 22KJB320027the startup grant of Xuzhou Medical University D2022003
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a malignant hematologic disease caused by gene mutations and genomic rearrangements in hematologic progenitors. The PHF6 (PHD finger protein 6) gene is highly conserved and located on the X chromosome in humans and mice. We found that PHF6 was highly expressed in AML cells with MLL rearrangement and was related to the shortened survival time of AML patients. In our study, we knocked out the Phf6 gene at different disease stages in the AML mice model. Moreover, we knocked down PHF6 by shRNA in two AML cell lines and examined the cell growth, apoptosis, and cell cycle. We found that PHF6 deletion significantly inhibited the proliferation of leukemic cells and prolonged the survival time of AML mice. Interestingly, the deletion of PHF6 at a later stage of the disease displayed a better anti-leukemia effect. The expressions of genes related to cell differentiation were increased, while genes that inhibit cell differentiation were decreased with PHF6 knockout. It is very important to analyze the maintenance role of PHF6 in AML, which is different from its tumor-suppressing function in T-cell acute lymphoblastic leukemia (T-ALL). Our study showed that inhibiting PHF6 expression may be a potential therapeutic strategy targeting AML patients.

Indexed as

Acute myeloid leukemia (AML)Cell differentiationLeukemia stem cells (LSCs)PHF6

Identifiers

PMID38336746
PMCPMC10858464
OpenAlexW4391693779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.